Zim Laboratories Ltd. · NSE:ZIMLAB
Zim Laboratories — Investor Presentation (May 2023)
31 slides from Zim Laboratories's investor presentation, May 20, 2023
Slide 1: Regulation 30 cover letter to stock exchanges
Ref No.: ZLL/CS/BM/BSE-NSE Date : 19.05.2023 BSE Limited, National Stock Exchange of India Limited Market Operations Dept. Listing Compliance Department P. J. Towers, Dalal Street, Exchange Plaza, Bandra-Kurla Complex, Mumbai- 400 001 Bandra (E), Mumbai – 400 051 Company Code- 541400 (Symbol - ZIMLA
Slide 2: ZIM Laboratories Limited Investor Presentation May 2023
ZIM Laboratories Limited Investor Presentation May 2023
Slide 3: Safe Harbour
SAFE HARBOUR The presentation has been prepared by ZIM Laboratories Limited (“ZIM” or the “Company”) solely for information purposes and does not constitute an offer to sell or recommendation or solicitation of an offer to subscribe for or purchase any securities and nothing contained herein shall f
Slide 4: Contents
CONTENTS BUSINESS FINANCIALS OUTLOOK & FOCUS CORPORATE 05 OVERVIEW 15 INCOME STATEMENT 22 OUTLOOK 25 BOARD OF DIRECTORS : ZIM 06 TRANSFORMATION INITIATIVES 16 BALANCE SHEET 23 FOCUS : FY24 26 BOARD OF DIRECTORS : ZHTL 07 BUSINESS HIGHLIGHTS 27 SUBSIDIARIES 08 FINANCIAL HIGHLIGHTS 13 R&D AT CORE
Slide 5: Business
BUSINESS
Slide 6: Overview
OVERVIEW ZIM develops and supplies differentiated generic Pharmaceutical and Nutraceutical products in Finished Formulations (FF) and Pre- Formulation Intermediates (PFI) in certain key therapeutic categories across RoW markets Our differentiation and value proposition is in our ability to develop a
Slide 7: Transformation Initiatives
TRANSFORMATION INITIATIVES Current Business Outlook Pharmaceuticals Nutraceuticals Pharmaceuticals; New Innovative Products (NIP) Nutraceuticals Generic Products Generic Products Branded Generics/OTF 10 2 4 PFI FF / OTF PFI FF New Products Dossiers filed Fillings (Various Stages of in the EU planned
Slide 8: Business Highlights
BUSINESS HIGHLIGHTS Moving up the Product Value Chain – Developing Value Added Generics 10 New Innovative Products(NIP) in various stages of development; 2 NIP filed in EU under ZIM’s name Strong and Experienced R&D ; Multiple BE Studies and Dossiers Comprehensive Dossiers for Key Developed and Phar
Slide 9: Financial Highlights
FINANCIAL HIGHLIGHTS FY23 Q4FY23 Total Operating Income for FY23 was Rs3,985Mn, up 19.5% YoY Total Operating Income for Q4FY23 was Rs1,054Mn, up 4.4% QoQ EBITDA for FY23 was Rs584Mn, up 28.7% YoY; EBITDA margins for FY23 EBITDA for Q4FY23 was Rs161Mn, up 3.9% QoQ ; EBITDA margins for were at 14.7% (
Slide 10: Exports Business
EXPORTS BUSINESS Exports business for FY23 was Rs 3,382Mn, up 25.2% from Rs 2,701Mn in FY22 MIX % : FY22 375 Contribution from Exports was 85% of our Total Operating Income 11% 258 Key regions for Exports during the year were MENA, SE Asia and Africa 8% Annual (Rs Mn) Quarterly (Rs Mn) 3,382 880 899
Slide 11: Domestic Business
DOMESTIC BUSINESS MIX % : FY22 (RS. 633 MN) For FY23, our domestic business was Rs 603Mn and comprised 15% of our Total 168 18 Operating Income 3% 46 26% 7% The domestic business includes sale to Central/ State Government, agencies owned by the Government and sale through deemed exports (products bi
Slide 12: Oral Thin Films
ORAL THIN FILMS During FY 23, we received Marketing Authorisation (MA) for EU market – Sildenafil Citrate in Spain. Several other products - Melatonin, Ondansetron, Vitamin D3, Methyl cobalamin, Levocetirizine, Sildenafil, Tadalafil etc. in various strengths have also received approvals and been com
Slide 13: Business Mix: Markets and Products
BUSINESS MIX : MARKETS AND PRODUCTS Region Wise Revenue Mix 7% 19% 21% 18% 26% 14% 25% 22% 7% 22% 23% 12% 13% 17% Diversified Geographical Mix; Hedge against adverse 24% 31% geo-political risks 37% 27% 19% 15% Focus shifting to developed markets in the EU and Pharmerging markets like LATAM, Brazil,
Slide 14: R&D at Core
R&D AT CORE R&D Expense Mix % Focus on using Differentiated Drug Delivery techniques Total R&D Spend as % of Total Operating Income Non – infringing development and manufacturing process using various technology platforms – - Micro - Emulsion Coating Technology (MECT) - Pellet Cold Forming Technolog
Slide 15: Financial Overview
FINANCIAL OVERVIEW
Slide 16: Income Statement
INCOME STATEMENT Change % Change % Particulars (Rs Mn) FY23 FY22 Q4FY23 Q3FY23 Q4FY22 (YoY) (QoQ) Total Operating Income 3,985 3,334 19.5% 1,054 1,010 4.4% 1,050 Other Income 64 44 46.2% 7 24 (70.8)% 16 Total Income 4,049 3,378 19.9% 1,061 1,034 2.6% 1,066 EBITDA 584 454 28.0% 161 155 3.9% 164 EBITD
Slide 17: Balance Sheet
BALANCE SHEET Particulars (Rs Mn) FY23 FY22 FY21 FY20 Gross Block – Tangible & Intangible Assets including WIP 2,257 1,920 1,762 1,689 Net Block – Tangible & Intangible Assets including WIP 1,357 1,174 1,172 1,256 Other Non- Current Assets 150 121 158 177 Current Assets 1,909 2,121 1,918 1,820 Total
Slide 18: Total Operating Income
TOTAL OPERATING INCOME Annual (Rs Mn) .8% R 12 C AG 3,985 98 3,334 3,073 2,777 52 153 165 3,887 3,282 2612 2,920 Total Operating Income grew to Rs3,985Mn in FY23 vs FY20 FY21 FY22 FY23 Rs3,334Mn in FY22; growth of 19.5%; CAGR of 12.8% over last 3 years (FY20-FY23) Operating Income Other operating in
Slide 19: EBITDA
EBITDA Annual (Rs Mn) and as % of Total Operating Income 2% 584 R 29. CAG 454 421 14.7% 13.7% 13.6% EBITDA grew to Rs 584Mn in FY23 vs Rs 454Mn in FY22 to in 271 spite of increase in operating costs and employee costs; CAGR of 9.8% 29.2% over last 3 years (FY20-FY23) FY20 FY21 FY22 FY23 Operating co
Slide 20: Profit After Tax
PROFIT AFTER TAX Annual (Rs Mn) and as % of Total Operating Income 244 8% R 94. CAG 146 6.1% 73 4.4% 33 2.4% 1.2% Profit After Tax(PAT) was Rs 244Mn in FY23 vs Rs 146Mn in FY22, FY20 FY21 FY22 FY23 growth of 67.2% YoY; CAGR of 94.8% over last 3 years (FY20-FY23) Quarterly (Rs Mn) and as % of Total O
Slide 21: Strengthening the Balance Sheet
STRENGTHENING THE BALANCE SHEET Gross Block Addition (Rs Mn) ROCE and ROE (in %) 16.8% 337 12.5% 10.8% 199 76 158 13.0% 40 73 5.4% 17 261 8.7% 159 16 141 4.7% 57 2.2% FY20 FY21 FY22 FY23 FY20 FY21 FY22 FY23 Tangible Assets Intangible Assets ROCE ROE Cash Flow from Operations (Rs Mn) Total Borrowings
Slide 22: Outlook and Focus
OUTLOOK AND FOCUS
Slide 23: Outlook
OUTLOOK We will continue to focus on our transformational growth journey The pharmaceutical business will continue to contribute over 75% of our overall operating income, the balance coming from Nutraceutical business PHARMACEUTICAL The building blocks of the healthcare industry and our business rem
Slide 24: Focus: FY24
FOCUS : FY24 We will continue to focus on entering the Key Developed and Pharmerging markets with new innovative generic products while growing our RoW business in line with historic trends Operations Capital R&D and Marketing Expenditure Quality Enhance the product pipeline Complete successful Audi
Slide 25: Corporate
CORPORATE
Slide 26: Board of Directors: ZIM
BOARD OF DIRECTORS : ZIM Dr. Anwar S. Daud Mr. Zulfiquar Kamal Mr. Niraj Dhadiwal Mr. Prakash Sapkal Chairman and Managing Director Director - Finance Director and Head – ODS Business, Formulation – Director - Business Development Domestic, RoW and Emerging Markets Dr. Kamlesh Shende Mr. Padmakar S.
Slide 27: Board of Directors: ZHTL
BOARD OF DIRECTORS : ZHTL ZIM Health Technologies Ltd., (ZHTL) supports technology and business related functions of ZIM in areas of product development, manufacturing and marketing of complex generic and high end pharmaceutical and healthcare products – particularly for the Developed and Pharmergin
Slide 28: Subsidiaries
SUBSIDIARIES ZIM Laboratories Limited, India Listed on BSE & NSE SIA ZIM Laboratories ZIM Laboratories FZE, ZIM Health Technologies ZIM Thinorals Private Limited, Latvia Sharjah , UAE Limited, India Limited, India (100% Subsidiary) (100% Subsidiary) (100% Subsidiary) (100% Subsidiary) For Product Fo
Slide 29: Shareholding
SHAREHOLDING Ownership % (On Mar ‘23) Traded Volume (In K) BSE+NSE During Q3, ZIM Laboratories Limited 22% 609 was listed on the National Stock 5% Exchange of India (NSE) in addition 5% to earlier BSE listing The company in Q3 issued Bonus Shares in the ratio of 2 (two) shares 35% 307 for 1 (one) ex
Slide 30: Share Price Movement
SHARE PRICE MOVEMENT ZIM (BSE) vs BSE S&P Healthcare Index 106.3 90.4 86.7 83 82.3 23,875 79 78.5 73 23,788 70.3 69 71.3 61 50.7 22,364 21,635 Mar-22 Apr-22 May-22 Jun-22 Jul-22 Aug-22 Sep-22 Oct-22 Nov-22 Dec-22 Jan-23 Feb-23 Mar-23 ZIM Avg. Closing Share Price BSE Health care index (Average Closin
Slide 31: Thank You
For Any Queries, please contact - Company Secretary at cs@zimlab.in For more information please visit www.zimlab.in THANK YOU